WallStreetZenWallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Gilead Sciences earnings were $8.1B for the trailing 12 months ending Sep 30, 2025, with 6,410% growth year over year. The latest GILD earnings report on Sep 30, 2025 announced Q3 2025 earnings of $3.1B, up 55.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GILD reported annual earnings of $480.0M, with -91.5% growth.

GILD past earnings growth

How has GILD's earnings growth performed historically?

Company
6,410%
Industry
344.33%
Market
55.48%
GILD's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
GILD's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
GILD's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

GILD earnings history

Current Revenue
$29.1B
Current Earnings
$8.1B
Current Profit Margin
27.9%
GILD's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

GILD Return on Equity

Current Company
40.7%
Current Industry
118.3%
Current Market
36.2%
GILD's Return on Equity (40.7%)... subscribe to Premium to read more.
High Return on Equity Performance

GILD undefined

Current Company
14.1%
Current Industry
11.9%
GILD is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when GILD announces earnings.

GILD undefined

Current Company
23.59%
Current Industry
19.9%
GILD has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GILD vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
GILD$13.67B$8.11B+46.04%$6.51
PFE$15.84B$9.83B+4.35%$1.72
AMGN$16.53B$7.01B+0.85%$13.03
SNY$18.05B$10.74B-2.50%$4.34
BMY$12.94B$6.04B-33.86%$2.97
View Top General Drug Manufacturer Stocks

Gilead Sciences Earnings Reports & History FAQ

What were Gilead Sciences's earnings last quarter?

On GILD's earnings call on Invalid Date, Gilead Sciences (NASDAQ: GILD) reported Q3 2025 earnings per share (EPS) of $2.46, up 146% year over year. Total GILD earnings for the quarter were $3.05 billion. In the same quarter last year, Gilead Sciences's earnings per share (EPS) was $1.00.

If you're new to stock investing, here's how to buy Gilead Sciences stock.

Is Gilead Sciences profitable or losing money?

As of the last Gilead Sciences earnings report, Gilead Sciences is currently profitable. Gilead Sciences's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $8.11 billion, a 6,336.51% increase year over year.

What was GILD's earnings growth in the past year?

As of Gilead Sciences's earnings date in Invalid Date, Gilead Sciences's earnings has grown 6,410% year over year. This is 6,065.67 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 344.33%. GILD earnings in the past year totalled $8.11 billion.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.